Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim

International Journal of Hematology

Volumn 102, Issue 3, 2015, Pages 259-270

  Cines, Douglas B ^a   Gernsheimer, Terry ^b,c   Wasser, Jeffrey ^d   Godeau, Bertrand ^e   Provan, Drew ^f   Lyons, Roger ^g   Altomare, Ivy ^h   Wang, Xuena ⁱ   Lopez, Angela ⁱ  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e HENRI MONDOR HOSPITAL   (France)

^f ROYAL LONDON HOSPITAL   (United Kingdom)

^g Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ AMGEN INC   (United States)

Author keywords

Immune thrombocytopaenia (ITP); Platelet; Romiplostim; Thrombopoietin (TPO)

Indexed keywords

AZATHIOPRINE; COLLAGEN; CORTICOSTEROID; DANAZOL; GLUCOCORTICOID; IMMUNOGLOBULIN; METHYLPREDNISOLONE; NEUTRALIZING ANTIBODY; PLACEBO; PREDNISONE; RETICULIN; RITUXIMAB; ROMIPLOSTIM; VINBLASTINE; VINCRISTINE; FC RECEPTOR; HYBRID PROTEIN; MPL PROTEIN, HUMAN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; APLASTIC ANEMIA; ARTICLE; BLEEDING; BONE MARROW; BONE MARROW BIOPSY; BRAIN EDEMA; BRAIN HEMORRHAGE; CARDIOPULMONARY INSUFFICIENCY; CAROTID ARTERY OBSTRUCTION; CATARACT; CAUCASIAN; CEREBROVASCULAR DISEASE; CHILD; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CONTUSION; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DRUG FATALITY; EAR BLEEDING; EAR DISEASE; EPISTAXIS; FEMALE; FUNGEMIA; GERIATRIC PATIENT; GINGIVA BLEEDING; HEADACHE; HEALTH CARE QUALITY; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART TAMPONADE; HEMATOLOGIC MALIGNANCY; HEMOLYSIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTESTINE INFARCTION; INTESTINE ISCHEMIA; KIDNEY ISCHEMIA; LISTERIOSIS; LIVER CANCER; LIVER FAILURE; LUNG CANCER; LUNG EMBOLISM; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYCOPLASMA PNEUMONIA; MYELOBLAST; OSTEOMYELITIS; PATIENT SAFETY; PETECHIA; PNEUMOCOCCAL INFECTION; PORTAL VEIN THROMBOSIS; PROMYELOCYTE; RHINOPHARYNGITIS; SPLENECTOMY; STREPTOCOCCUS PNEUMONIA; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS; ADOLESCENT; AGONISTS; FOLLOW UP; PRESCHOOL CHILD; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN;

EID: 84941258916     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1837-6     Document Type: Article

References (28)

1. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.
2. Molineux G. The development of romiplostim for patients with immune thrombocytopenia. Ann N Y Acad Sci. 2011;1222:55–63.
3. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395–403.
4. ® (romiplostim) prescribing information, Amgen.
5. Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol. 2013;91:423–36.
6. Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2010;8:1372–82.
7. Janssens A, Rodeghiero F, Anderson D, Chong B, Boda Z, Pabinger I, et al. Results from a phase IV open-label study evaluating changes in bone marrow morphology in adult immune thrombocytopenia (ITP) patients receiving romiplostim: analysis of the 1- and 2-year romiplostim cohorts. Blood (ASH Annual Meeting Abstracts). 2013;122:2312.
8. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672–81.
9. Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118:28–36.
10. Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized phase III clinical trial. Int J Hematol. 2011;94:71–80.
11. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889–99.
12. Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006;135:547–53.
13. Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, et al. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;90:157–65.
14. Janssens A, Tarantino MD, Bird R, Mazzucconi MG, Boccia RVV, Lopez-Fernandez MF, et al. Final results from an international, multi-center, single-arm study evaluating the safety and efficacy of romiplostim in adults with primary immune thrombocytopenia (ITP). Blood (ASH Annual Meeting Abstracts). 2011;118:3279.
15. Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser JS, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haemat. 2013;161:411–23.
16. Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, et al. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Int J Hematol. 2012;95:652–9.
17. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009;114:3748–56.
18. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40.
19. Langeberg W, Eisen M, Schoonen WM, Gamelin L, Stryker S. A systematic literature review and meta-analysis of the risk of thromboembolic events in patients with immune thrombocytopenia (ITP) in observational studies. Blood (ASH Annual Meeting Abstracts). 2012;120:2187.
20. Enger C, Bennett D, Forssen U, Fogarty PF, McAfee AT. Comorbidities in patients with persistent or chronic immune thrombocytopenia. Int J Hematol. 2010;92:289–95.
21. Norgaard M, Severinsen MT, Lund Maegbaek M, Jensen AO, Cha S, Sorensen HT. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2012;159:109–11.
22. Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010;95:1167–75.
23. Severinsen MT, Engebjerg MC, Farkas DK, Jensen AO, Norgaard M, Zhao S, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2011;152:360–2.
24. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379:244–9.
25. Mufti G, Bagg A, Hasserjian R, Bain B, Kuter D, Dreiling L, et al. Bone marrow reticulin in patients with immune thrombocytopenic purpura. Blood (ASH Annual Meeting Abstracts). 2006;108:3982.
26. Ghanima W, Geyer JT, Lee CS, Boiocchi L, Imahiyerobo AA, Orazi A, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99:937–44.
27. Brynes RK, Orazi A, Wong RSM, Bakshi K, Bailey CK, Brainsky A. A longitudinal prospective study evaluating the effects of eltrombopag treatment on bone marrow in patients with chronic immune thrombocytopenia: interim analysis at 1 year. Blood (ASH Annual Meeting Abstracts). 2012;120:2195.
28. Stasi R, Newland A, Godeau B, Priego V, Viallard J-F, Lopez Fernandez MF, et al. An interim analysis of a phase 2, single-arm study of platelet responses and remission rates in patients with immune thrombocytopenia (ITP) receiving romiplostim. Blood (ASH Annual Meeting Abstracts). 2013;122:1074.